BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999.

马萨诸塞州贝德福德市。--（商业新闻短讯）--斯托克治疗公司（纳斯达克股票代码：STOK）是一家致力于通过RNA药物上调蛋白质表达来解决严重疾病的根本原因的生物技术公司，今天宣布其以每股13.50美元的价格向公众增发555555股普通股，并以每股13.4999美元的价格购买总计3703730股普通股的预先融资权证，以代替向选择的投资者发行的普通股。

The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke. The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares of common stock in connection with the offering.

在扣除承销折扣和佣金以及斯托克城应付的其他发售费用之前，此次发售的总收益预计为1.25亿美元。预计本次发行将于2024年4月2日左右结束，但须符合惯例的结束条件。斯托克城还授予承销商30天的期权，以购买与此次发行相关的额外1388893股普通股。

All of the shares of common stock and pre-funded warrants are being offered by Stoke..

斯托克城正在发售所有普通股和预支认股权证。。

J.P. Morgan Securities LLC is acting as sole book-running manager for the offering.

J、 摩根大通证券有限责任公司是此次发行的唯一账簿管理人。

Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of its product candidates, including late-stage development of STK-001 and further development of STK-002, developing additional product candidates, working capital, capital expenditures, and for other general corporate purposes..

斯托克城计划使用拟议发售的净收益及其现有现金和现金等价物，为候选产品的研究、临床和工艺开发和制造提供资金，包括STK-001的后期开发和STK-002的进一步开发，开发额外的候选产品、营运资金、资本支出以及其他一般公司用途。。

The shares and pre-funded warrants are being offered by Stoke pursuant to a registration statement on Form S-3 (No. 333-265107) that was declared effective by the Securities and Exchange Commission (the “SEC”) on May 31, 2022. A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC.

斯托克城根据S-3表格（编号333-265107）上的登记声明发售股票和预支认股权证，该登记声明于2022年5月31日由证券交易委员会（“SEC”）宣布生效。与本次发行相关的初步补充招股说明书和随附招股说明书已提交给SEC。

Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, and when available, the final prospectus supplement, may be obtained from J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com.

初步补充招股说明书和随附的与本次发行有关的补充招股说明书的副本，以及最终补充招股说明书的副本，可通过以下方式获得：J.P.Morgan Securities LLC，转交：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，New York 11717，电话866-803-9204或电子邮件prospectus-eq_fi@jpmchase.com.

Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov..

初步补充招股说明书和随附招股说明书的电子副本也将在美国证券交易委员会的网站上提供，网址为http://www.sec.gov..

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Stoke, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售斯托克城任何证券的要约或邀约购买斯托克城任何证券的要约，也不构成在任何州或司法管辖区的证券法规定的登记或资格之前，在任何州或司法管辖区出售这些证券是非法的。。

About Stoke Therapeutics

关于中风治疗学

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

Stoke Therapeutics（纳斯达克股票代码：STOK）是一家生物技术公司，致力于通过使用基于RNA的药物上调蛋白质表达来解决严重疾病的根本原因。利用斯托克专有的探戈（靶向增强核基因输出）方法，斯托克正在开发反义寡核苷酸（ASO）以选择性恢复蛋白质水平。

Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.

斯托克的第一种化合物STK-001正在进行临床试验，用于治疗Dravet综合征，这是一种严重的进行性遗传性癫痫。Dravet综合征是由单倍剂量不足引起的许多疾病之一，其中约50%的正常蛋白质水平降低会导致疾病。斯托克正在开发STK-002，用于治疗常染色体显性遗传性视神经萎缩（ADOA），这是最常见的遗传性视神经疾病。

Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts..

斯托克最初的重点是中枢神经系统和眼睛的单倍剂量不足和疾病，尽管概念证明已在其他器官，组织和系统中得到证实，这支持了其对专有方法的广泛潜力的信念。斯托克城总部位于马萨诸塞州贝德福德，在马萨诸塞州剑桥设有办事处。。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding expectations of market conditions, timing of the closing, the satisfaction of customary closing conditions related to the offering and the anticipated gross proceeds of the offering and the use thereof.

本新闻稿包含1995年《私人证券诉讼改革法》中“安全港”条款所指的前瞻性声明，包括但不限于关于市场条件预期、交割时间、与发行相关的习惯交割条件的满足情况、发行的预期总收益及其使用的声明。

Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause our results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: statements the Company makes regarding the Company’s ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates, including STK-001; the timing of data readouts and interim and final results of preclinical and clinical trials; the receipt and timing of potential regulatory decisions; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company’s ability to fund development activities and achieve development goals into 2025; the Company’s ability to protect its intellectual property; the direct or indirect impact of global business, political and macroeconomic conditions, including inflation, interest rate volatility, .

前瞻性陈述可以通过以下词语来识别：“预期”，“打算”，“计划”，“目标”，“寻求”，“相信”，“项目”，“估计”，“预期”，“战略”，“未来”，“可能”，“可能”，“应该”，“将会”以及对未来时期的类似引用。这些前瞻性陈述涉及风险和不确定性，以及假设，如果这些假设被证明不正确或没有完全实现，可能会导致我们的结果与这些前瞻性陈述中明示或暗示的结果产生重大差异，包括但不限于与以下相关的风险和不确定性：公司就公司推进、获得监管部门批准并最终商业化其候选产品（包括STK-001）的能力所作的陈述；数据读取的时间以及临床前和临床试验的中期和最终结果；潜在监管决定的接收和时间安排；临床试验的阳性结果可能不会在后续试验中复制，或者早期临床试验的成功可能无法预测后期试验的结果；公司资助发展活动并实现2025年发展目标的能力；公司保护其知识产权的能力；全球商业、政治和宏观经济状况的直接或间接影响，包括通货膨胀、利率波动。